FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308383986> ?p ?o ?g. }

• W4308383986 abstract "<h3>Background</h3> Botensilimab (BOT) promotes optimized T cell priming, activation and memory formation by strengthening antigen presenting cell/T cell co-engagement. As an Fc-enhanced next-generation anti-CTLA-4 antibody, BOT also promotes intratumoral Treg depletion and reduces complement fixation. We present results from patients with metastatic solid tumors treated with BOT±balstilimab (BAL; anti-PD-1) in an expanded phase IA/B study; NCT03860272. <h3>Methods</h3> Patients received either BOT monotherapy at 0.1-3 mg/kg every 3 weeks (Q3W), BOT monotherapy 1 or 2mg/kg every 6 weeks (Q6W), BOT 0.1-2mg/kg Q6W+BAL 3 mg/kg every 2 weeks, or a fixed-dose of BOT 150mg Q6W+BAL 450mg Q3W. Unconfirmed responses are included. Of the 44 BOT monotherapy patients, 13 crossed over to combination. <h3>Results</h3> 142 patients (98 combination, 44 monotherapy [13 crossover]) were evaluable for efficacy/safety (treated as of April 7, 2022 with ≥1 Q6W tumor-imaging assessment). Patients had immunologically cold and/or immunotherapy resistant tumors and were heavily pretreated: 61% received ≥3 prior lines of therapy including 34% prior immunotherapy. Median follow-up was 6.1 months. Disease-specific combination therapy cohorts are being expanded with BOT at 1 or 2mg/kg or 150mg+BAL (including 4 crossover patients): (1) microsatellite stable (MSS) colorectal cancer (n=44, ORR 25%), (2) platinum resistant ovarian cancer (n=18, ORR 28%), (3) sarcoma (n=12, ORR 42%, and (4) PD-(L)1 relapsed/refractory non-small cell lung cancer (n=3, ORR 67%). The ORR was 22% (22/98; 3 CR/19 PR) with median duration of response [DOR] not reached (range,1.4+ to 19.5+ months) in all combination patients (BAL+BOT 0.1-2 mg/kg or 150 mg); 13/22 responses are ongoing. In addition, 15% (2/13) monotherapy patients achieved PR after crossing over to combination therapy. The ORR was 11% (5/44; 1 CR/4 PR) in all monotherapy patients (BOT 0.1-3 mg/kg). Responses were independent of PD-L1 expression and tumor mutation burden. Further evaluation of biomarkers is ongoing including paired biopsies (before/during treatment). Grade 1/2, 3 or 4 treatment-related adverse events (TRAE) occurred in 88%, 29%, 2% respectively. Diarrhea/colitis (19%) was the only grade 3/4 TRAE occurring in ≥5% of patients. There were no cases of hypophysitis or myocarditis. Pneumonitis occurred in 4 patients (3%). Two patients had grade 5 TRAEs (enterocolitis, colonic perforation). <h3>Conclusions</h3> BOT±BAL demonstrates remarkable activity in heavily pretreated patients with solid tumors historically unresponsive to immunotherapy. The safety profile is consistent with the mechanism of action of BOT. Randomized studies in MSS CRC, pancreatic cancer, and melanoma are planned to open this year. <h3>Trial Registration</h3> NCT03860272" @default.
• W4308383986 created "2022-11-11" @default.
• W4308383986 creator A5004418792 @default.
• W4308383986 creator A5004799762 @default.
• W4308383986 creator A5005462156 @default.
• W4308383986 creator A5013744957 @default.
• W4308383986 creator A5018028908 @default.
• W4308383986 creator A5020479411 @default.
• W4308383986 creator A5024182274 @default.
• W4308383986 creator A5028581221 @default.
• W4308383986 creator A5028823704 @default.
• W4308383986 creator A5030261899 @default.
• W4308383986 creator A5031609312 @default.
• W4308383986 creator A5035164790 @default.
• W4308383986 creator A5035554702 @default.
• W4308383986 creator A5035580621 @default.
• W4308383986 creator A5044840107 @default.
• W4308383986 creator A5047608547 @default.
• W4308383986 creator A5050232356 @default.
• W4308383986 creator A5050740210 @default.
• W4308383986 creator A5052730435 @default.
• W4308383986 creator A5060495866 @default.
• W4308383986 creator A5065012486 @default.
• W4308383986 creator A5067347913 @default.
• W4308383986 creator A5068892140 @default.
• W4308383986 creator A5069690249 @default.
• W4308383986 creator A5070975837 @default.
• W4308383986 creator A5071193838 @default.
• W4308383986 creator A5071322358 @default.
• W4308383986 creator A5073582280 @default.
• W4308383986 creator A5079409805 @default.
• W4308383986 creator A5080150466 @default.
• W4308383986 creator A5081273660 @default.
• W4308383986 creator A5082674870 @default.
• W4308383986 creator A5084347950 @default.
• W4308383986 creator A5085454526 @default.
• W4308383986 creator A5086974953 @default.
• W4308383986 date "2022-11-01" @default.
• W4308383986 modified "2023-09-23" @default.
• W4308383986 title "778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors" @default.
• W4308383986 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0778" @default.
• W4308383986 hasPublicationYear "2022" @default.
• W4308383986 type Work @default.
• W4308383986 citedByCount "0" @default.
• W4308383986 crossrefType "proceedings-article" @default.
• W4308383986 hasAuthorship W4308383986A5004418792 @default.
• W4308383986 hasAuthorship W4308383986A5004799762 @default.
• W4308383986 hasAuthorship W4308383986A5005462156 @default.
• W4308383986 hasAuthorship W4308383986A5013744957 @default.
• W4308383986 hasAuthorship W4308383986A5018028908 @default.
• W4308383986 hasAuthorship W4308383986A5020479411 @default.
• W4308383986 hasAuthorship W4308383986A5024182274 @default.
• W4308383986 hasAuthorship W4308383986A5028581221 @default.
• W4308383986 hasAuthorship W4308383986A5028823704 @default.
• W4308383986 hasAuthorship W4308383986A5030261899 @default.
• W4308383986 hasAuthorship W4308383986A5031609312 @default.
• W4308383986 hasAuthorship W4308383986A5035164790 @default.
• W4308383986 hasAuthorship W4308383986A5035554702 @default.
• W4308383986 hasAuthorship W4308383986A5035580621 @default.
• W4308383986 hasAuthorship W4308383986A5044840107 @default.
• W4308383986 hasAuthorship W4308383986A5047608547 @default.
• W4308383986 hasAuthorship W4308383986A5050232356 @default.
• W4308383986 hasAuthorship W4308383986A5050740210 @default.
• W4308383986 hasAuthorship W4308383986A5052730435 @default.
• W4308383986 hasAuthorship W4308383986A5060495866 @default.
• W4308383986 hasAuthorship W4308383986A5065012486 @default.
• W4308383986 hasAuthorship W4308383986A5067347913 @default.
• W4308383986 hasAuthorship W4308383986A5068892140 @default.
• W4308383986 hasAuthorship W4308383986A5069690249 @default.
• W4308383986 hasAuthorship W4308383986A5070975837 @default.
• W4308383986 hasAuthorship W4308383986A5071193838 @default.
• W4308383986 hasAuthorship W4308383986A5071322358 @default.
• W4308383986 hasAuthorship W4308383986A5073582280 @default.
• W4308383986 hasAuthorship W4308383986A5079409805 @default.
• W4308383986 hasAuthorship W4308383986A5080150466 @default.
• W4308383986 hasAuthorship W4308383986A5081273660 @default.
• W4308383986 hasAuthorship W4308383986A5082674870 @default.
• W4308383986 hasAuthorship W4308383986A5084347950 @default.
• W4308383986 hasAuthorship W4308383986A5085454526 @default.
• W4308383986 hasAuthorship W4308383986A5086974953 @default.
• W4308383986 hasBestOaLocation W43083839861 @default.
• W4308383986 hasConcept C121608353 @default.
• W4308383986 hasConcept C126322002 @default.
• W4308383986 hasConcept C142424586 @default.
• W4308383986 hasConcept C143998085 @default.
• W4308383986 hasConcept C159654299 @default.
• W4308383986 hasConcept C203014093 @default.
• W4308383986 hasConcept C2776999253 @default.
• W4308383986 hasConcept C2777701055 @default.
• W4308383986 hasConcept C71924100 @default.
• W4308383986 hasConcept C86803240 @default.
• W4308383986 hasConcept C87355193 @default.
• W4308383986 hasConcept C90924648 @default.
• W4308383986 hasConceptScore W4308383986C121608353 @default.
• W4308383986 hasConceptScore W4308383986C126322002 @default.
• W4308383986 hasConceptScore W4308383986C142424586 @default.
• W4308383986 hasConceptScore W4308383986C143998085 @default.
• W4308383986 hasConceptScore W4308383986C159654299 @default.
• W4308383986 hasConceptScore W4308383986C203014093 @default.
• W4308383986 hasConceptScore W4308383986C2776999253 @default.

• next